Apelin and Sirtuin 1 Dysregulation induce Endocrine and Metabolic Disorders in Chronic Disease by Ian James Martins* in GJEM
Interests
in chronic diseases have increased globally with the global death
related to the increased chronic disease rate [1] with the most
prevalent chronic disease such as cardiovascular disease linked to the
metabolic syndrome and non alcoholic fatty liver disease (NAFLD). The
role of the peptide apelin to the global obesity and diabetes epidemic
has become of concern with relevance to its role in ischemic heart
failure [2-4], treatment for obesity/diabetes [5-7], neuroendocrine
function [3,8], glucose/energy metabolism [5], kidney disease [1,3,9]
and NAFLD [10]. Analysis of plasma apelin levels and their regulation by
nutrigenomic diets, exercise, drugs, lifestyle changes has become
critical to prevent and reverse various chronic diseases that are linked
to cardiovascular disease and NAFLD. Apelin
is a peptide and present in a number of tissues such as the GItract,
stomach, heart, brain and adipose tissue [1]. The apelin receptor is a G
protein coupled receptor (GPCR) and referred to as the APJ receptor and
present in various tissues and in neurons of the hypothalamus [3].
